1. 3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting. (March 2019) Authors: Pivot, X.; Bondarenko, I.; Dvorkin, M.; Sarosiek, T.; Wojtukiewicz, M.; Shparyk, Y.; Kim, Y.; Lim, J. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗